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RAD51D mutations have been recently identified in breast (BC) and ovarian cancer (OC) families. Although an etiological role
in OC appears to be present, the association of RAD51D mutations and BC risk is more unclear. We aimed to determine the
prevalence of germline RAD51D mutations in Spanish BC/OC families negative for BRCA1/BRCA2 mutations. We analyzed 842
index patients: 491 from BC/OC families, 171 BC families, 51 OC families and 129 patients without family history but with
early-onset BC or OC or metachronous BC and OC. Mutation detection was performed with high-resolution melting, denaturing
high-performance liquid chromatography or Sanger sequencing. Three mutations were found in four families with BC and OC
cases (0.82%). Two were novel: c.1A>T (p.Met1?) and c.66712_667123del, leading to the exon 7 skipping and one previously
described: c.674C>T (p.Arg232*). All were present in BC/OC families with only one OC. The c.66712_667123del cosegregated
in the family with one early-onset BC and two bilateral BC cases. We also identified the c.629C>T (p.Ala210Val) variant, which
was predicted in silico to be potentially pathogenic. About 1% of the BC and OC Spanish families negative for BRCA1/BRCA2
are carriers of RAD51D mutations. The presence of several BC mutation carriers, albeit in the context of familial OC, suggests
an increased risk for BC, which should be taken into account in the follow-up and early detection measures. RAD51D testing
should be considered in clinical setting for families with BC and OC, irrespective of the number of OC cases in the family.
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Ovarian cancer (OC) represents the eighth most commonly
diagnosed cancer among women in the world, and causes
more deaths per year than any other cancer of the female
reproductive system.1 On a worldwide basis, 224,747 new
cases (standardized incidence rate of 6.3 per 100,000 women)
are diagnosed and 140,163 women die of OC annually (esti-
mated in 2008).1 Mortality is high because women typically
present with late-stage disease when the overall 5-year rela-
tive survival rate is 45% (reviewed in Ref.2). The most impor-
tant risk factor is having a family history of the disease
(reviewed in Ref.3). Approximately 25% of newly diagnosed
cases are due to a hereditary mutation in a single gene: 18%
in BRCA1 or BRCA2; 5% in other genes of the Fanconi-
Anemia-BRCA DNA repair pathway, including MRE11,
BRIP1, PALB2, RAD51C, CHEK2, NBN, RAD50 and BARD1;
1% in genes of DNA mismatch repair pathways (MLH1,
MSH2, MSH6 and PMS2) and less than 1% in other genes
such as TP53.3–5
The identification of RAD51C mutations in families with
breast and ovarian cancer (BC/OC) prompted investigations
on the role of another RAD51 paralog, RAD51D, in cancer
susceptibility.6 The protein encoded by RAD51D is a member
of the RAD51 protein family. The RAD51 protein is a key
player in the homologous recombinational repair pathway
and its activity appears to be strictly regulated by a number
of cofactors including five RAD51 paralogs, namely RAD51B,
RAD51C, RAD51D, XRCC2 and XRCC3.7 RAD51D protein
forms a complex with RAD51B, RAD51C and XRCC2
(BCDX2 complex),8 which is responsible for RAD51 recruit-
ment or stabilization at DNA damage sites.9 Additionally, it
has been described that RAD51D plays a role in telomere
protection against attrition and chromosome fusion.10 Love-
day et al.6 identified inactivating mutations in RAD51D in
eight of the 911 British cases with a familial history of BC/
OC (0.88%) and in one of the 1,060 British controls (0.09%).
The association was principally found with OC because the
higher prevalence of mutations was present in families with
more than one case of OC: four mutations in 235 families
with two or more cases of OC (1.7%) and three mutations
among the 59 families with three or more cases of OC
(5.09%).6 By contrast, no mutations were found in 737 unre-
lated individuals with only a history of familial BC. The
authors estimated an OC relative risk of 6.30 and a BC rela-
tive risk of 1.32 for RAD51D mutation carriers.6 Four further
studies have explored the role of RAD51D mutations in BC/
OC families as well as in unselected OC cases.11–14 These
works show that RAD51D is an OC predisposition gene, but
more studies in familial and sporadic OC series would be of
value to further clarify the risks associated to OC and BC.3
The aim of our study was to determine the prevalence of
germline RAD51D mutations in a cohort of Spanish BC and/




The study included a total of 842 unrelated index cases: 713
cases from families with a history of OC and/or BC cases
and 129 cases with only a personal history of early-onset BC
or OC or concomitant BC and OC. Six centers from Spain
have contributed to this study: Hospital Universitari Vall
d’Hebron, Barcelona (HUVH) (N 5 281); Hospital Clınico
San Carlos (HCSC), Madrid (N 5 168); Centro Nacional de
Investigaciones Oncologicas (CNIO), Madrid (N 5 165);
Fundacion Publica Galega de Medicina Xenomica (FPGMX),
Santiago de Compostela (N 5 94); Hospital de la Santa Creu
i Sant Pau (HSCSP), Barcelona (N 5 79) and Instituto de
Biologıa y Genetica Molecular (IBGM), Valladolid (N 5 55).
All index cases were previously screened for point mutations
and large rearrangements in BRCA1 and BRCA2 genes and
no disease-causing mutation was identified.
The studied families were as follows: (i) 491 families with
one or more OC cases and one or more BC cases (77% of
them had at least one case diagnosed before age 50); (ii) 171
site-specific female BC families with two or more cases (94%
of families with at least one case diagnosed before age 50)
and (iii) 51 families with two or more OC cases. All the pro-
bands analyzed, except 19 healthy cases, were diagnosed with
BC (291) or OC (120) or BC 1 OC (55) or other cancers
(6). The study also included patients without family history:
65 BC patients (95% of them diagnosed before age 50), 38
women with OC (82% of them diagnosed before age 50) and
26 with BC and OC. This study was approved by the corre-
sponding institutional ethical committees and informed con-
sent was obtained from all the participants.
Mutation analysis of RAD51D
Genomic DNA was extracted from patient peripheral blood
samples by standard methods. The screening for germline
variation of the coding region and exon–intron boundaries of
What’s new?
RAD51D mutations have recently been identified in breast (BC) and ovarian (OC) cancer families. Although RAD51D mutations
are associated with hereditary OC, such an association is less clear in BC. This study determined the prevalence of germline
RAD51D mutations in Spanish BC/OC families testing negative for BRCA1/BRCA2 mutations. RAD51D mutations were found in
almost 1% (4/491) of BC/OC families. These families had only one OC case, with some carriers presenting BC, suggesting
that RAD51D testing should be offered to all BC/OC families. The existence of an increased risk of BC should be considered










Gutierrez-Enrıquez et al. 2089
Int. J. Cancer: 134, 2088–2097 (2014) VC 2013 UICC
the RAD51D was performed using different techniques: direct
sequencing (HUVH, FPGMX and HSCSP), high-resolution
melting (HCSC and IBGM) and denaturing high-
performance liquid chromatography (CNIO). All sequence
variants were named according to Human Genome Variation
Society (HGVS) nomenclature using the NCBI transcript ID
NM_002878.3 (or its equivalent sequence from Ensembl tran-
script ID ENST00000345365) as a reference sequence. The
exons were numbered according to the NCBI Reference
Sequence: NG_031858.1.
In silico analysis of identified variants
All RAD51D genetic variants (coding and noncoding) were
analyzed for their potential effect on splicing. For this analy-
sis the variants are reported according to their location, rela-
tive to the 50 (donor) and 30 (acceptor) consensus sites
described by Cartegni et al.,15 that is 11 bases for the donor
site (from the three last exonic to the eight first intronic
bases) and 14 bases for the acceptor site (from the 12 last
intronic to the first two exonic bases). Thus, the variants
were classified in three categories: variants occurring at con-
sensus donor or acceptor splice sites, exonic positions outside
the consensus sites and intronic positions outside the consen-
sus sites (Supporting Information Table S1). Splicing predic-
tions were performed with Human Splicing Finder,
SpliceSiteFinder-like, NNSplice, MaxEntScan and Genscan by
using Alamut software v2.1 (Interactive biosoftware). For the
nucleotide variants located in consensus sites, if the score
estimated by MaxEntScan and SpliceSiteFinder-like was 15
and 5% lower than the wild-type score, respectively, the three
remaining prediction algorithms were used (modified from
Ref.16). Then, a consensus decrease across all algorithms was
considered as indicative of disruption of normal splicing.6
For variants occurring outside consensus splice sites, the
exon skipping, the use of a cryptic site or of a de novo splice
site, had to be predicted by at least the MaxEntScan and
SpliceSiteFinder-like algorithms. We also evaluated the pre-
dicted effects of RAD51D missense variants on protein using
PolyPhen, SIFT and Align GVGD by using Alamut v2.1 and
Condel integrated score (http://bg.upf.edu/condel/home).17
cDNA analysis
To analyze splice-site mutations total RNA was purified from
peripheral blood lymphocytes using the RNA blood mini kits
(Qiagen, Hilden, Germany) or TRIzol (Invitrogen, Carlsbad,
CA, US). At least two RNAs extracted from normal individu-
als were used as controls. To generate complementary DNA
(cDNA), 1 mg RNA was retrotranscribed with either the
superScriptII kit (Invitrogen, Carlsbad, CA, US) or the High-
Capacity RNA-to-cDNA Master Mix (Applied Biosystems,
Foster City, Ca, US). The cDNA was amplified with two sets
of primers spanning exons 1–7 (1F-cctctctaggaaggggtaggg
and 7R-cagttcctgaagaaccagtca) and exons 5–10 (5F-caggc-
taaaacccaggatga and 10R-ccaggtcccaatgtctacca). The products
were electrophoresed on agarose gels and the resolved cDNA
fragments were either directly sequenced or extracted from
the gel using a QIAquick Gel Extraction Kit (Qiagen, Hilden,
Germany) before bidirectionally sequenced using BigDye Ter-
minator v3.1 Cycle Sequencing Kit (Applied Biosystems, Fos-
ter city, Ca, US).
Results
We screened the RAD51D gene for germline sequence varia-
tions in a total of 842 Spanish index cases with either a fam-
ily history of BC and/or OC or a personal history of BC or
OC with early-onset or concurrent BC and OC. We identified
25 different RAD51D sequence variants (Table 1). Two var-
iants overtly pathogenic and one likely pathogenic were
detected in four families out of the 491 families with BC/OC
cases. One of the clear mutations was a deletion affecting a
canonical donor splice site leading to loss of exon 7 and a
premature stop codon in the RAD51D transcript in one fam-
ily (c.66712_667123del, p.Val193Alafs*4) (Fig. 1a). A non-
sense variant in exon 8 was identified in two unrelated
families (c.694C>T, p.Arg232*). Moreover, a substitution
likely pathogenic, c.1A>T (p.Met1?), affecting the translation
initiation codon was also detected in one family with BC/OC
cases. The in silico analysis predicted that this variant would
cause the activation of a cryptic acceptor site at c.15 (Table
1). No evidence of a new aberrant transcript was obtained in
the cDNA analysis of this variant and both wild-type and
variant alleles were equally present in the sequence of the
cDNA (Fig. 1b), suggesting that the c.1A>T does not induce
a major alteration in the transcript expression. The cDNA
analysis further revealed two alternative transcripts, one con-
taining an out-of-frame skip of exon 3 and the other an in-
frame skip of exons 3, 4 and 5 that were present both in the
patient and all negative control samples (data not shown).
The delta 3 isoform was also found in controls by Osher
et al.11 The delta 3, 4 and 5 isoform is described in NCBI
database as an alternative transcript NM_133629.2, also
known as isoform 4 or TRAD-d3.
The families carrying the RAD51D pathogenic variants
presented only one OC case (Fig. 2). The splicing variant
c.66712_667123del was present in the index case, a woman
diagnosed of bilateral BC at the ages of 29 and 40, and in
two sisters, one diagnosed with BC at the age of 49 and the
other with bilateral BC at the age of 43 (Fig. 2). The non-
sense variant c.694C>T (p.Arg232*) was present in a woman
diagnosed with OC at the age of 44 in one family and in a
woman with bilateral OC at the age of 42 in the other family
(Fig. 2). In one of these families three healthy sisters and one
healthy brother also carried this nonsense variant (Fig. 2).
Both the affected and healthy carriers (six subjects) also car-
ried the missense change c.715C>T (p.Arg239Trp) in exon 8
(Table 1). The c.1A>T (p.Met1?) mutation was present in a
woman with BC and OC diagnosed at the age of 51 and 64,
respectively (Fig. 2).
In addition, we also identified seven RAD51D nonsynony-
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rs4796033) and c.698A>G (p.Glu233Gly; rs28363284) are
reported in 1000 genomes and in NHLBI Exome Sequencing
Project (ESP) databases as well as in previous reports18–21 to
have allele frequencies near to or greater than 1% (Table 1). Five
missense variants, c.26G>C (p.Cys9Ser; rs140825795), c.355T>C
(p.Cys119Arg; rs201313861), c.629C>T (p.Ala210Val),
c.695G>A (p.Arg232Gln; rs28363283) and c.715C>T
(p.Arg239Trp), have been reported with a minor allele frequency
(MAF) of 0.0001 to 0.003 in either 1000 genomes and ESP data-
bases as well as in previous studies11,14,22 (Table 1). Both the
c.26G>C and the c.715C>T variants (this last occurring in all
the carriers of the deleterious c.694C>T variant) were predicted
to be damaging by two of the four programs used to analyze the
variant effect on the protein (Table 1). Interestingly, the nonsy-
nonymous variant c.629C>T (p.Ala210Val) located in exon 7 of
RAD51D was predicted to be deleterious by the four programs
used, and is only reported in ESP project with an allele fre-
quency of 0.0001 (Table 1). Similarly, it is also inferred to be
potentially damaging based on the degree of conservation of the
amino acid among the RAD51 paralogs (Fig. 3). This nonsynon-
ymous variant was identified in a woman affected with OC at
the age of 60 and a strong family history of BC/OC cases: one
relative with BC and OC diagnosed both at the age of 40, one
with bilateral OC diagnosed at the ages of 50 and 55 and one
case of endometrial cancer at the age of 58.
We also detected two synonymous changes: c.234C>T
(rs9901455) with a MAF >1% and c.879G>A with a MAF
<1%. None of these variants were predicted to alter splicing
(Table 1 and Supporting Information Table S1). In addition,
the mutation screening also revealed 13 noncoding changes:
two variants located in the 50UTR of the gene and 11 intronic
sequence alterations. The intronic variants c.480175T>G,
c.903153C>T and c.904-11T>A were predicted to alter the
splicing (Table 1 and Supporting Information Table S1).
Unfortunately, no RNA samples were available to study their
potential splicing effect.
Discussion
We identified germline RAD51D deleterious mutations in
0.82% of the families with at least one OC case and one BC
case (4/491). Noteworthy, the four carrier families had seven
BC cases. Five were diagnosed before the age 50, including
two bilateral BC cases. Previous reports found similar preva-
lences of RAD51D pathogenic variants from 0.57 in Canadian
and Belgian BC/OC families11 to 0.88 in British BC/OC fami-
lies.6 Pelttari et al.12 described the presence of a founder
RAD51D mutation in 2.9% of the Finish patients with a fam-
ily history of both BC and OC. In contrast, Thompson
et al.13 detected no deleterious RAD51D changes in 303 Aus-
tralian BC/OC families. It should be noted that in none of
these studies, including ours, the screening techniques used
do not allow to detect deletions/duplications affecting com-
plete exons or the entire gene.
We did not identify any deleterious RAD51D variant in
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no OC cases, which is consistent with other studies that did
not find any association between RAD51D mutations and BC
risk.6,12–14 Interestingly, no pathogenic variant was detected
in our series of 51 pedigrees with only an OC family history.
Our data agree with that obtained in previous reports in
which a limited number of this type of families was analyzed:
eight families12 and 16 families.13 Although more studies to
assess the implication of RAD51D in families with two or
more OC cases are required, the results obtained in our
larger cohort may suggest that other genes could confer a
specific susceptibility to familial OC.
The alteration of the translation initiation codon (c.1A>T,
p.Met1?) and the variant leading to a skipping of exon 7
(c.66712_667123del, p. Val193Alafs*4) had not been
Figure 1. RNA analysis of two RAD51D pathogenic mutations. (a) Analysis of c.66712_667123del; gDNA: electropherogram obtained from
genomic DNA showing the 22-bp deletion in heterozygosity in intron 7; cDNA: agarose bands and sequences from cDNA amplification, showing
the loss of exon 7 in the mutation carrier (Ca). Ctr: control cDNA. (b) Analysis of c.1A>T; sequences obtained from gDNA and cDNA showing the
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Figure 2. Pedigrees of four families with RAD51D pathogenic mutations. The arrow indicates the family proband. Individuals with ovarian
cancer are shown as gray circles. Individuals with breast cancer are shown as black circles. Other cancers are shown as unfilled circle. BC:
breast cancer; OC: ovarian cancer; BCb: bilateral breast cancer; OCb: bilateral ovarian cancer; HN: head and neck cancer; END: endometrial
cancer; GC: gastric cancer; LG: lung cancer; LV: liver cancer. AThe carriers of the nonsense mutation also presented the missense variant
c.715C>T.
Figure 3. Conservation of site of the RAD51D missense variant c.629C>T (p.Ala210Val). RAD51 and its five paralogs were aligned using the
Clustal Omega program (multiple sequence alignment program for proteins, http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool5
clustalo). Fully or partially conserved residues are coloured. An * (asterisk) indicates positions that have a single, fully conserved residue.
A: (colon) indicates conservation between groups of strongly similar properties—scoring >0.5 in the Gonnet PAM 250 matrix. A. (period)
indicates conservation between groups of weakly similar properties—scoring 0.5 in the Gonnet PAM 250 matrix. [Color figure can be
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previously described. Given that other single base-pair substi-
tutions located within the ATG translation initiation codon in
different genes have been reported to perturb the initiation
step of translation, and to reduce translational efficiency in
vivo (reviewed in Ref.23), we consider the substitution c.1A>T
(p.Met1?) pathogenic.
The nonsense variant in exon 9 (c.694C>T, p.Arg232*)
has also been identified in a group of American women with
OC who had not been selected for age of onset or family his-
tory.14 Interestingly, all carriers of this nonsense alteration in
our series (two with OC and four healthy) and the affected
carrier found by Wickramanyake et al.14 also carried the
nonsynonymous variant in exon 8 c.715C>T. Altogether,
these data suggest that both variants are probably in cis and
the nonsense nucleotide alteration could be a founder
mutation.
The role of rare RAD51D missense variants in OC risk is
not yet clear. Loveday et al.6 did not find overall differences
in the frequency of nontruncating RAD51D variants between
cases and controls. Rare nonsynonymous variants have been
further identified among families with BC only13 and unse-
lected women with OC,14 but besides in silico analysis, were
not further assessed for pathogenicity. We identified a nonsy-
nonymous variant, c.629C>T (p.Ala210Val), which is poten-
tially pathogenic based on SIFT, PolyPhen, Align GVGD and
Condel predictions, and the amino acid conservation among
the RAD51 paralogs (Fig. 3). The change Ala210Val is
located in the C-terminal ATPase domain of RAD51D that is
conserved among eukaryotic proteins (http://www.ncbi.nlm.-
nih.gov/Structure/cdd/cddsrv.cgi?uid5238543) as well as
among the five human RAD51 paralogs, and is closely related
to the C-terminal domain of RAD51.24 However, functional
assays and cosegregation data with OC in the family are war-
ranted to clarify the impact of this variant.
The studies published to date show that RAD51D muta-
tions are more likely to be found in families with two or more
OC cases and at least one BC case.6,11 In contrast, in our study
all RAD51D mutations were present in families reported with
only one OC case and one or more BC cases (Table 2). Our
findings suggest that RAD51D testing should be offered to
affected women with a familiar history of BC/OC regardless of
the number of OC cases in the family. Moreover, in our series
the splicing variant c.66712_667123del was present in three
women with BC (two of them had bilateral BC), and only one
relative with OC. Loveday et al.,6 Osher et al.11 and Pelttari
et al.12 also described RAD51D deleterious variants in women
affected with BC in BC/OC families. Although the frequency
of RAD51D mutations in BC families with no OC could be
anticipated to be very low,6 these findings support a higher
incidence of breast tumors associated to RAD51D mutations,
albeit in the context of familial OC.
The apparent excess of BC carriers in these families could
be attributed to an ascertainment bias selecting OC cases
with a close family history of BC,6 but also to the existence
of other unknown variants that could modify the BC risk
associated with RAD51D mutations in these families and
warrants further investigations.11,12 The early onset of BC in
these families agrees with this latter hypothesis. Combining
all data of RAD51D-associated BC cases published to
date6,11,12 and our data, a mean age of 44.77 years for BC
onset was obtained (Supporting Information Table S2), which
is lower than the mean age for sporadic breast tumors (an
average age of onset in their 50s for Caucasian women refer-
enced in Haffty et al.25) and similar to the mean age of BC
in BRCA1 or BRCA2 mutation carriers reported in diverse
populations: 43.6 years (Spanish), 41.6 (British) and 44.1
years (Canadian) for BRCA1 and 42.8 (Spanish), 45.2 (Brit-
ish) and 47.3 years (Canadians) for BRCA2.26–28 Alterna-
tively, specific mutation risks may be attributed to the type
and location of the variants.12 Considering the mutations
described in previously published articles and in this article,
we did not observe any association between the BC or OC
risk and location of the mutations along RAD51D (data not
shown).
In conclusion, we identified three pathogenic variants,
c.66712_667123del, c.1A>T and c.694C>T in four out of
the 491 probands (0.82%) from OC and BC families. Our
results agree with the association of RAD51D mutations with
the presence of OC cases in the family. Interestingly, all patho-
genic variants were present in families reported with only one
OC case, suggesting that RAD51D testing should be offered to
any affected BC or OC subject irrespective of the number of
OC cases in the family. In the c.66712_667123del proband’s
family, both the proband and two relatives carried the mutated
allele and were affected with BC (two of them bilaterals).
Despite the modest proportion of RAD51D deleterious
Table 2. Prevalence of RAD51D pathogenic variants reported according to the number of ovarian cases in breast and ovarian cancer families
Reference
N mutation carriers/n BC
1 1OC families (%)
N mutation carriers/n BC
1 2OC families (%)
N mutation carriers/n BC
1 3OV families (%) Total
Loveday et al.6 1/617 (0.16) 4/235 (1.7) 3/59 (5.1) 8/911 (0.9)
Oscher et al.11 0/124 (0) 1/43 (2.32) 0/8 (0) 1/175 (0.5)
Pelttari et al.12 ns ns ns 3/105 (2.9)
Thompson et al.13 0/ns 0/ns 0/ns 0/303 (0)
Our study 4/282 (1.4) 0/189 (0) 0/20 (0) 4/491 (0.8)










2096 RAD51D germline mutations in breast and ovarian Spanish families
Int. J. Cancer: 134, 2088–2097 (2014) VC 2013 UICC
mutations identified, genetic testing of this gene should be
considered into the clinical setting, at least for families with
BC and OC. The presence of several BC mutation carriers,
albeit in the context of familial OC, suggests an increased risk
of this type of cancer, which should be considered when set-
ting the follow-up and prevention measures, and future spe-
cific treatments. Additional studies in familial BC/OC series
would be of value to provide more complete information on
the actual risk of OC, as well as the potential risks of BC and
any other cancers.
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